ArticleDermatology and therapy2026
Abrocitinib Achieves Early and Complete/Near-Complete Skin Clearance Plus Itch-Free State in Atopic Dermatitis: Phase 3 Pooled Post Hoc Analysis.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A phase 3 multi-center, long-term extension study investigating the efficacy and safety of abrocitinib, with or without topical medications, administered to subjects aged 12 years and older with moderate to severe atopic dermatitis
A phase 3 randomized, double-blind, double-dummy, placebo-controlled, parallel group, multi-center study investigating the efficacy and safety of pf-04965842 and dupilumab in comparison with placebo in adult subjects on background topical therapy, with moderate to severe atopic dermatitis
A phase 3b randomized, double-blind, double-dummy, active controlled multi-center study assessing the efficacy and safety of abrocitinib compared with dupilumab in adult participants on background topical therapy with moderate to severe atopic dermatitis
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAbrocitinib, a Janus kinase inhibitor, is approved for patients with moderate-to-severe atopic dermatitis.
methodsThis post hoc analysis assessed the onset and depth of response of abrocitinib 100 or 200 mg in achieving the stringent outcome of ≥ 90% improvement from baseline in the Eczema Area and Severity Index score and Peak Pruritus Numerical Rating score of 0 to 1 (EASI-90 + PP-NRS0/1) in the JADE DARE (NCT04345367) and JADE COMPARE (NCT03720470) clinical trials, and previous dupilumab inadequate responders in the JADE EXTEND (NCT03422822) clinical trial.
resultsHigher proportions of patients achieved EASI-90 + PP-NRS0/1 with abrocitinib 200 mg (5.8%) versus dupilumab (1.1%) as early as week 2 in JADE DARE. In JADE COMPARE, 27.1% of patients treated with abrocitinib 200 mg achieved EASI-90 + PP-NRS0/1 compared with 20.2% with abrocitinib 100 mg, 15.5% with dupilumab, and 5.4% with placebo at week 16. Similar proportions of patients achieved this endpoint irrespective of baseline itch. Patients whose disease did not respond to dupilumab were able to achieve EASI-90 + PP-NRS0/1 with abrocitinib 200 or 100 mg in JADE EXTEND (16.7% and 18.5%, respectively).
conclusionThese findings suggest that minimal disease activity can be attained in patients with moderate-to-severe atopic dermatitis treated with abrocitinib, regardless of prior dupilumab exposure.
trial registrationClinicaltrials.gov identifiers: NCT04345367 (JADE DARE), NCT03720470 (JADE COMPARE), NCT03422822 (JADE EXTEND).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.